Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To evaluate safety and efficacy of axitinib in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer

Next Previous
Search
Trial Profile

To evaluate safety and efficacy of axitinib in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use

Most Recent Events

  • 01 Oct 2017 Results assessing safety and efficacy of axitinib in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer, were published in the European Journal of Endocrinology.
  • 05 Oct 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top